Cargando…
S201: FINAL 7-YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALYSIS OF MURANO: VENETOCLAX-RITUXIMAB (VENR)-TREATED PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL)
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428463/ http://dx.doi.org/10.1097/01.HS9.0000967716.49281.3f |
| _version_ | 1785090475577835520 |
|---|---|
| author | Kater, Arnon Harrup, Rosemary Kipps, Thomas J Eichhorst, Barbara Owen, Carolyn J Assouline, Sarit Lamanna, Nicole Robak, Tadeusz de la Serna, Javier Jaeger, Ulrich Cartron, Guillaume Montillo, Marco Mellink, Clemens Chyla, Brenda Thadani-Mulero, Maria Lefebure, Marcus Jiang, Yanwen Millen, Rosemary Boyer, Michelle Seymour, John F |
| author_facet | Kater, Arnon Harrup, Rosemary Kipps, Thomas J Eichhorst, Barbara Owen, Carolyn J Assouline, Sarit Lamanna, Nicole Robak, Tadeusz de la Serna, Javier Jaeger, Ulrich Cartron, Guillaume Montillo, Marco Mellink, Clemens Chyla, Brenda Thadani-Mulero, Maria Lefebure, Marcus Jiang, Yanwen Millen, Rosemary Boyer, Michelle Seymour, John F |
| author_sort | Kater, Arnon |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10428463 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104284632023-08-17 S201: FINAL 7-YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALYSIS OF MURANO: VENETOCLAX-RITUXIMAB (VENR)-TREATED PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL) Kater, Arnon Harrup, Rosemary Kipps, Thomas J Eichhorst, Barbara Owen, Carolyn J Assouline, Sarit Lamanna, Nicole Robak, Tadeusz de la Serna, Javier Jaeger, Ulrich Cartron, Guillaume Montillo, Marco Mellink, Clemens Chyla, Brenda Thadani-Mulero, Maria Lefebure, Marcus Jiang, Yanwen Millen, Rosemary Boyer, Michelle Seymour, John F Hemasphere Oral Sessions Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428463/ http://dx.doi.org/10.1097/01.HS9.0000967716.49281.3f Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Oral Sessions Kater, Arnon Harrup, Rosemary Kipps, Thomas J Eichhorst, Barbara Owen, Carolyn J Assouline, Sarit Lamanna, Nicole Robak, Tadeusz de la Serna, Javier Jaeger, Ulrich Cartron, Guillaume Montillo, Marco Mellink, Clemens Chyla, Brenda Thadani-Mulero, Maria Lefebure, Marcus Jiang, Yanwen Millen, Rosemary Boyer, Michelle Seymour, John F S201: FINAL 7-YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALYSIS OF MURANO: VENETOCLAX-RITUXIMAB (VENR)-TREATED PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL) |
| title | S201: FINAL 7-YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALYSIS OF MURANO: VENETOCLAX-RITUXIMAB (VENR)-TREATED PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL) |
| title_full | S201: FINAL 7-YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALYSIS OF MURANO: VENETOCLAX-RITUXIMAB (VENR)-TREATED PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL) |
| title_fullStr | S201: FINAL 7-YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALYSIS OF MURANO: VENETOCLAX-RITUXIMAB (VENR)-TREATED PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL) |
| title_full_unstemmed | S201: FINAL 7-YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALYSIS OF MURANO: VENETOCLAX-RITUXIMAB (VENR)-TREATED PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL) |
| title_short | S201: FINAL 7-YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALYSIS OF MURANO: VENETOCLAX-RITUXIMAB (VENR)-TREATED PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL) |
| title_sort | s201: final 7-year follow up and retreatment substudy analysis of murano: venetoclax-rituximab (venr)-treated patients with relapsed/refractory chronic lymphocytic leukemia (r/r cll) |
| topic | Oral Sessions |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428463/ http://dx.doi.org/10.1097/01.HS9.0000967716.49281.3f |
| work_keys_str_mv | AT katerarnon s201final7yearfollowupandretreatmentsubstudyanalysisofmuranovenetoclaxrituximabvenrtreatedpatientswithrelapsedrefractorychroniclymphocyticleukemiarrcll AT harruprosemary s201final7yearfollowupandretreatmentsubstudyanalysisofmuranovenetoclaxrituximabvenrtreatedpatientswithrelapsedrefractorychroniclymphocyticleukemiarrcll AT kippsthomasj s201final7yearfollowupandretreatmentsubstudyanalysisofmuranovenetoclaxrituximabvenrtreatedpatientswithrelapsedrefractorychroniclymphocyticleukemiarrcll AT eichhorstbarbara s201final7yearfollowupandretreatmentsubstudyanalysisofmuranovenetoclaxrituximabvenrtreatedpatientswithrelapsedrefractorychroniclymphocyticleukemiarrcll AT owencarolynj s201final7yearfollowupandretreatmentsubstudyanalysisofmuranovenetoclaxrituximabvenrtreatedpatientswithrelapsedrefractorychroniclymphocyticleukemiarrcll AT assoulinesarit s201final7yearfollowupandretreatmentsubstudyanalysisofmuranovenetoclaxrituximabvenrtreatedpatientswithrelapsedrefractorychroniclymphocyticleukemiarrcll AT lamannanicole s201final7yearfollowupandretreatmentsubstudyanalysisofmuranovenetoclaxrituximabvenrtreatedpatientswithrelapsedrefractorychroniclymphocyticleukemiarrcll AT robaktadeusz s201final7yearfollowupandretreatmentsubstudyanalysisofmuranovenetoclaxrituximabvenrtreatedpatientswithrelapsedrefractorychroniclymphocyticleukemiarrcll AT delasernajavier s201final7yearfollowupandretreatmentsubstudyanalysisofmuranovenetoclaxrituximabvenrtreatedpatientswithrelapsedrefractorychroniclymphocyticleukemiarrcll AT jaegerulrich s201final7yearfollowupandretreatmentsubstudyanalysisofmuranovenetoclaxrituximabvenrtreatedpatientswithrelapsedrefractorychroniclymphocyticleukemiarrcll AT cartronguillaume s201final7yearfollowupandretreatmentsubstudyanalysisofmuranovenetoclaxrituximabvenrtreatedpatientswithrelapsedrefractorychroniclymphocyticleukemiarrcll AT montillomarco s201final7yearfollowupandretreatmentsubstudyanalysisofmuranovenetoclaxrituximabvenrtreatedpatientswithrelapsedrefractorychroniclymphocyticleukemiarrcll AT mellinkclemens s201final7yearfollowupandretreatmentsubstudyanalysisofmuranovenetoclaxrituximabvenrtreatedpatientswithrelapsedrefractorychroniclymphocyticleukemiarrcll AT chylabrenda s201final7yearfollowupandretreatmentsubstudyanalysisofmuranovenetoclaxrituximabvenrtreatedpatientswithrelapsedrefractorychroniclymphocyticleukemiarrcll AT thadanimuleromaria s201final7yearfollowupandretreatmentsubstudyanalysisofmuranovenetoclaxrituximabvenrtreatedpatientswithrelapsedrefractorychroniclymphocyticleukemiarrcll AT lefeburemarcus s201final7yearfollowupandretreatmentsubstudyanalysisofmuranovenetoclaxrituximabvenrtreatedpatientswithrelapsedrefractorychroniclymphocyticleukemiarrcll AT jiangyanwen s201final7yearfollowupandretreatmentsubstudyanalysisofmuranovenetoclaxrituximabvenrtreatedpatientswithrelapsedrefractorychroniclymphocyticleukemiarrcll AT millenrosemary s201final7yearfollowupandretreatmentsubstudyanalysisofmuranovenetoclaxrituximabvenrtreatedpatientswithrelapsedrefractorychroniclymphocyticleukemiarrcll AT boyermichelle s201final7yearfollowupandretreatmentsubstudyanalysisofmuranovenetoclaxrituximabvenrtreatedpatientswithrelapsedrefractorychroniclymphocyticleukemiarrcll AT seymourjohnf s201final7yearfollowupandretreatmentsubstudyanalysisofmuranovenetoclaxrituximabvenrtreatedpatientswithrelapsedrefractorychroniclymphocyticleukemiarrcll |